Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Damage Repair (DDR) and Transcriptional Regulation Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for C1D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | C1D Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed to preserve native phosphorylation states critical for DNA-repair complex assembly. |
View C1D Products |
| Gene Delivery | C1D Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional rescue assays. |
View C1D Products |
| Benchmark Ab | Anti-C1D Recombinant Antibody High-affinity sequence-verified positive control for immunoprecipitation (IP) and Western Blot. |
View C1D Products |
| Validator | C1D siRNA Set Target-specific knockdown pool for functional validation and specificity screening. |
View C1D Products |
| Related Target A | PRKDC (DNA-PKcs) Direct physical interaction partner of C1D; essential mediator of non-homologous end joining (NHEJ) DNA repair. |
View PRKDC Products |
| Related Target B | NR1D1 (Rev-Erb Alpha) Transcriptional repressor partner interacting with C1D to modulate circadian rhythms and metabolic oncology pathways. |
View NR1D1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native Phosphorylation for Protein-Protein Interaction (PPI) | HEK293 mammalian expression system guarantees correct post-translational modifications, crucial for C1D-PRKDC complexing. |
| Off-Target Screening against Related Corepressors | Homolog and corepressor panel proteins strictly verified by mass spectrometry to ensure zero cross-contamination. |
| Lack of Validated Positive Controls | Clinical-grade recombinant benchmark antibodies included for assay standardization. |
| False Positive Knockdown Signalling | Sequence-verified siRNA pools with non-targeting controls included for biological specificity checks. |
Live C1D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for C1D therapeutics is intensifying, with major players shifting focus from traditional global DNA damage response (DDR) inhibitors to targeted protein-protein interaction (PPI) disruptors and RNA-targeting modalities. As first-generation broad-spectrum DDR therapies reach clinical ceilings due to systemic toxicity, the next wave of R&D is targeting the precise C1D-mediated NHEJ repair pathway to selectively sensitize homologous recombination (HR)-deficient tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Biotech Startups | Breast Cancer, Osteosarcoma, Glioblastoma | High-throughput interaction assays (Need ultra-pure, native-state C1D and PRKDC proteins) |
| siRNA / RNAi Therapeutics | RNA Therapeutics Specialists | Advanced Solid Tumors, Refractory Cancers | In vitro knockdown validation (Need sequence-verified siRNA sets and Lentivirus for rescue) |
| Combination Therapies (with PARP inhibitors) | Global Pharma Players | BRCA-mutant and HR-proficient malignancies | Synergy screening models (Need robust stable cell lines expressing C1D and associated DDR targets) |